Plozasiran Sodium Patent Expiration

Plozasiran Sodium was first introduced by Arrowhead Pharmaceuticals Inc in its drug Redemplo on Nov 18, 2025.


Plozasiran Sodium Patents

Given below is the list of patents protecting Plozasiran Sodium, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Redemplo US10597657 Sep 10, 2038 Arrowhead
Redemplo US11214801 Sep 10, 2038 Arrowhead
Redemplo US12365899 Sep 10, 2038 Arrowhead
Redemplo US10294474 Mar 07, 2037 Arrowhead
Redemplo US11174481 Mar 07, 2037 Arrowhead



Plozasiran Sodium's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Plozasiran Sodium Generic API Manufacturers

Given below is the list of companies who have filed for Plozasiran Sodium generic, along with the locations of their manufacturing plants worldwide.